CSIMarket
 


Biogen Inc   (BIIB)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

BIIB's EPS from Cont. Operations Growth by Quarter and Year

Biogen Inc 's EPS from Cont. Operations results by quarter and year




BIIB EPS from Cont. Operations (in $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 2.33 8.11 4.74
III Quarter September - 4.47 8.40 7.17
II Quarter June - 9.60 7.85 4.18
I Quarter March 2.70 8.10 7.17 5.55
FY   2.70 24.50 31.53 21.64



BIIB EPS from Cont. Operations first quarter 2021 Y/Y Growth Comment
Biogen Inc reported drop in EPS from Cont. Operations in the first quarter by -66.67% to $ 2.70 , from the same quarter in 2020.
The fall in the first quarter Biogen Inc 's EPS from Cont. Operations compares unfavorably to the Company's average EPS from Cont. Operations rise of 36.17%.

Looking into first quarter results within Biotechnology & Drugs industry 12 other companies have achieved higher EPS from Cont. Operations growth. While Biogen Inc ' s EPS from Cont. Operations meltdown of -66.67% ranks overall at the positon no. 1100 in the first quarter.




BIIB EPS from Cont. Operations ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - -71.27 % 71.1 % -
III Quarter September - -46.79 % 17.15 % 23.62 %
II Quarter June - 22.29 % 87.8 % 2.7 %
I Quarter March -66.67 % 12.97 % 29.19 % 59.94 %
FY   - -22.3 % 45.7 % 81.39 %

Financial Statements
Biogen Inc 's first quarter 2021 EPS from Cont. Operations $ 2.70 BIIB's Income Statement
Biogen Inc 's first quarter 2020 EPS from Cont. Operations $ 8.10 Quarterly BIIB's Income Statement
New: More BIIB's historic EPS from Cont. Operations Growth >>


BIIB EPS from Cont. Operations (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - -47.87 % -3.45 % -33.89 %
III Quarter September - -53.44 % 7.01 % 71.53 %
II Quarter June - 18.52 % 9.48 % -24.68 %
I Quarter March 15.88 % -0.12 % 51.27 % -
FY (Year on Year)   - -22.3 % 45.7 % 81.39 %




EPS from Cont. Operations first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #13
Healthcare Sector #87
Overall #1100

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
475 % 36.17 % -71.22 %
(Sep. 30, 2006)   (Dec 31 2020)
EPS from Cont. Operations first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #13
Healthcare Sector #87
Overall #1100
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
475 % 36.17 % -71.22 %
(Sep. 30, 2006)   (Dec 31 2020)

EPS from Cont. Operations by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Biogen Inc 's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
118.75 % 9.92 % -53.44 %
(March 31, 2006)   (Sep 30 2020)


BIIB's I. Quarter Q/Q EPS from Cont. Operations Comment
Biogen Inc achieved in the I. Quarter 2021 above company average sequential EPS from Cont. Operations jump of 15.88%, to $ 2.70 , from $2.33 in the forth quarter.
BIIB is undergoing a remarkable growth, not only reporting higher then regular gain, and also increasing speed, Gonçalo Soares, an industry expert from Porto mentioned.

Within Biotechnology & Drugs industry only one company achieved higher sequential EPS from Cont. Operations growth. While Biogen Inc 's EPS from Cont. Operations growth quarter on quarter, overall rank is 86.


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #6
Overall #86
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #6
Overall #86
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
118.75 % 9.92 % -53.44 %
(March 31, 2006)   (Sep 30 2020)


BIIB's I. Quarter Q/Q EPS from Cont. Operations Comment
Biogen Inc achieved in the I. Quarter 2021 above company average sequential EPS from Cont. Operations jump of 15.88%, to $ 2.70 , from $2.33 in the forth quarter.
BIIB is going from strength to strength, not just recording better then normal growth, but also accelerating rate.

Within Biotechnology & Drugs industry only one company achieved higher sequential EPS from Cont. Operations growth. While Biogen Inc 's EPS from Cont. Operations growth quarter on quarter, overall rank is 86.


Biogen Inc 's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
Cumulative EPS from Cont. Operations 12 Months Ending $ 19.10 $ 24.50 $ 30.28 $ 34.21 $ 32.46
Y / Y EPS from Cont. Operations Growth (TTM) -41.15 % -22.28 % 7.53 % 27.03 % 39.55 %
Year on Year EPS from Cont. Operations Growth Overall Ranking # 163 # 1159 # 635 # 26 # 15
Seqeuential EPS from Cont. Operations Change (TTM) -22.04 % -19.08 % -11.49 % 5.39 % 2.95 %
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # 1355 # 1588 # 1487 # 607 # 609




Cumulative EPS from Cont. Operations growth Comment
Biogen Inc 's cumulative 12 months EPS from Cont. Operations continue to drop, but on the faster rate at -41.15% year on year, at Mar 31 2021 compare to the -22.28% decrease at Dec 31 2020. If the Biogen Inc 's fiscal year would end at Mar 31 2021, annual EPS from Cont. Operations would be $19 .

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While Total ranking has impoved so far to 163, from total ranking in previous quarter at 1159.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
422.22 %
14.04 %
-86.96 %
(Sep. 30, 2006)   (Sep 30 2020)

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 2
Healthcare Sector # 10
Overall # 163

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
1811.11 %
71.57 %
-79.07 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 102
S&P 500 # 1354
Cumulative EPS from Cont. Operations growth Comment
Biogen Inc 's cumulative 12 months EPS from Cont. Operations continue to drop, but on the faster rate at -41.15% year on year, at Mar 31 2021 compare to the -22.28% decrease at Dec 31 2020. If the Biogen Inc 's fiscal year would end at Mar 31 2021, annual EPS from Cont. Operations would be $19 .

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While Total ranking has impoved so far to 163, from total ranking in previous quarter at 1159.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
422.22 %
14.04 %
-86.96 %
(Sep. 30, 2006)   (Sep 30 2020)


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 2
Healthcare Sector # 10
Overall # 163

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
1811.11 %
71.57 %
-79.07 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 102
S&P 500 # 1354




Other EPS from Cont. Operations Growth
Biotechnology & Drugs Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
BIIB's EPS from Cont. Operations Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for BIIB's Competitors
EPS from Cont. Operations Growth for Biogen Inc 's Suppliers
EPS from Cont. Operations Growth for BIIB's Customers

You may also want to know
BIIB's Annual Growth Rates BIIB's Profitability Ratios BIIB's Asset Turnover Ratio BIIB's Dividend Growth
BIIB's Roe BIIB's Valuation Ratios BIIB's Financial Strength Ratios BIIB's Dividend Payout Ratio
BIIB's Roa BIIB's Inventory Turnover Ratio BIIB's Growth Rates BIIB's Dividend Comparisons



Companies with similar EPS from Cont. Operations drop for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Mar 31 2021
Merck and Co Inc -0.79%$ -0.787 
Abbvie Inc -0.99%$ -0.990 
Prestige Consumer Healthcare Inc -3.51%$ -3.507 
Eli Lilly And Company-6.88%$ -6.875 
Amgen Inc -7.77%$ -7.767 
Phibro Animal Health Corp-9.09%$ -9.091 
Baxter International Inc -9.23%$ -9.231 
Atrion Corporation-11.88%$ -11.875 
Neurocrine Biosciences Inc -15.00%$ -15.000 
Msa Safety Inc-16.96%$ -16.964 
Corcept Therapeutics Inc-23.08%$ -23.077 
National Research Corporation-23.40%$ -23.404 
Iradimed Corp-26.67%$ -26.667 
Catalyst Pharmaceuticals Inc -30.00%$ -30.000 
Alpha Pro Tech Ltd-31.71%$ -31.707 
Acadia Healthcare Company Inc -34.21%$ -34.211 
Teleflex Incorporated-43.46%$ -43.463 
Anika Therapeutics Inc -51.22%$ -51.220 
Vyne Therapeutics Inc -55.79%$ -55.789 
Viemed Healthcare Inc -63.64%$ -63.636 
Edwards Lifesciences Corporation-63.76%$ -63.758 
Biogen Inc -66.67%$ -66.667 
Endo International Plc-71.01%$ -71.014 
The Pennant Group Inc -72.73%$ -72.727 
Supernus Pharmaceuticals inc -73.17%$ -73.171 
Biomarin Pharmaceutical Inc-77.78%$ -77.778 
United Therapeutics Corporation-79.94%$ -79.936 
Align Technology inc -86.85%$ -86.853 
Amneal Pharmaceuticals Inc -93.59%$ -93.590 
Assertio Holdings inc -94.83%$ -94.828 


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

QNBC's Profile

Stock Price

QNBC's Financials

Business Description

Fundamentals

Charts & Quotes

QNBC's News

Suppliers

QNBC's Competitors

Customers & Markets

Economic Indicators

QNBC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071